Replimune Group Inc., REPL, FDA Calendar, PDUFA Date

Company Name	Replimune Group Inc. REPL
Drug Name	RP1 (Resubmitted BLA)
Event Name	FDA decision on RP1 in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen
Event Date	04/10/2026
Outcome Date	04/10/2026
Outcome	FDA issued a Complete Response Letter for RP1 again on Apr.10, 2026
Drug Status	FDA issued a Complete Response Letter for RP1 on July 22, 2025
Rival Drugs
Market Potential
Other Approvals
News

Return to FDA Calendar

Slide Shows